{
    "Trade/Device Name(s)": [
        "Control-IQ Technology"
    ],
    "Submitter Information": "Tandem Diabetes Care, Inc.",
    "510(k) Number": "K232382",
    "Predicate Device Reference 510(k) Number(s)": [
        "K200467"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QJI"
    ],
    "Summary Letter Date": "November 3, 2023",
    "Summary Letter Received Date": "August 8, 2023",
    "Submission Date": "August 7, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1356"
    ],
    "Regulation Name(s)": [
        "Interoperable Automated Glycemic Controller"
    ],
    "Analyte Class(es)": [
        "endocrine",
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose",
        "Insulin (delivered)"
    ],
    "Specimen Type(s)": [],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Compatible ACE insulin pumps",
        "Compatible integrated continuous glucose monitors (iCGM)",
        "t:slim X2 insulin pump (as example from clinical study)"
    ],
    "Method(s)/Technology(ies)": [
        "Automated glycemic control",
        "Software algorithm",
        "Integration with continuous glucose monitoring and insulin pump"
    ],
    "Methodologies": [
        "Automated insulin delivery",
        "Closed-loop control"
    ],
    "Submission Type(s)": [
        "Software",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for Tandem Diabetes Care Control-IQ Technology, a software-only interoperable automated glycemic controller for insulin delivery in Type 1 diabetes.",
    "Indications for Use Summary": "Intended for use with compatible continuous glucose monitors and alternate controller enabled insulin pumps to automatically adjust insulin delivery for management of Type 1 diabetes in persons aged 2 years and older; for single patient use and requires prescription.",
    "fda_folder": "Clinical Chemistry"
}